Showing 2231-2240 of 3402 results for "".
Natural Products that Exhibit Antifungal Activity
https://practicaldermatology.com/topics/general-topics/natural-products-that-exhibit-antifungal-activity/20360/Can natural products fight the fungus among us?Inside the Minds of Acne Patients
https://practicaldermatology.com/columns/clinical-focus-1/inside-the-minds-of-acne-patients/23634/Recommendations on how to start developing a treatment plan with its roots in the psychology of the acne patient.Rebooting the C. acnes Narrative
https://practicaldermatology.com/topics/acne-rosacea/rebooting-the-ic-acnesi-narrative/23623/New Directions in Acne Care
https://practicaldermatology.com/topics/acne-rosacea/new-directions-in-acne-care/23515/Recent developments and therapeutic advancements continue to improve outcomes in the management of this common, inflammatory disease.Second Primary Tumors and Immune Checkpoint Inhibitors: What Do We Know?
https://practicaldermatology.com/topics/skin-cancer-photoprotection/second-primary-tumors-and-immune-checkpoint-inhibitors-what-do-we-know/23452/New evidence reveals a potential link between ICI treatment and risk for secondary cancers.Kaposi Sarcoma in HIV-negative Men: A Case Series
https://practicaldermatology.com/youngmd-connect/resident-resource-center/kaposi-sarcoma-in-hiv-negative-men-a-case-series/23158/Papa in at Valeant, J&J Acquires Neostrata, Celebrity Lip Envy
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-papa-in-at-valeant-j-j-acquires-neostrata-celebrity-lip-envy/18772/This edition of DermWireTV brings news that Joseph C. Papa has left Perrigo Company plc, a top five global over-the-counter consumer goods and pharmaceutical company, to take the helm as CEO at Valeant Pharmaceuticals. He will replace J. Micheal Pearson. Valeant also concluded its investigation arouDermwireTV — Valeant Ups Allergan Bid, Nestle Buys Injectables, and Allergan Makes Its Case
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-valeant-ups-allergan-bid-nestle-buys-injectables-and-allergan-makes-its-case/19128/BREAKING NEWS: Valeant has increased its offer for Allergan to $72 per share. Read more. Valeant sells the rights to its aesthetic injectables to Nestle, while Allergan touts physician support and challenges Valeant's business model. In this week's edition of DermWireTV, learn about Valeant's latesClinical Case Report: Severe Allergic Contact Dermatitis of Eyelids: When Topical and Oral Steroids Are Not an Option
https://practicaldermatology.com/topics/general-topics/clinical-case-report-severe-allergic-contact-dermatitis-of-eyelids-when-topical-and-oral-steroids-are-not-an-option/21878/Topical calcineurin inhibitors may present a therapeutic option for contact dermatitis of the eyelids.Cosmetics Challenge: Six Strategies for Scientific Skincare, Part 2 of 2
https://practicaldermatology.com/topics/general-topics/cosmetics-challenge-six-strategies-for-scientific-skincare-part-2-of-2/21934/Clinicians who are familiar with scientifically proven skincare ingredients, knowledgeable about formulations, and adept at combining topical products can help patients achieve or maintain cosmetic rejuvenation goals.